JDIT 2015 0301 014.pdf


Preview of PDF document jdit-2015-0301-014.pdf

Page 1 23473

Text preview


Journal of Diagnostic Imaging in Therapy. 2015; 2(1): 30-102

Patching

schizophrenia, multiple sclerosis and cerebral ischemia. Cardiovascular diseases, along with
underlying conditions such as inflammation, sarcoidosis, atherosclerosis, and infections of implants
and prosthetics are routinely assessed using [18F]FDG PET. Diabetes alters the distribution of
[18F]FDG, which can affect diagnosis of other diseases. The effects of anti-diabetic drugs on glucose
metabolism and activation of brown adipose tissue as a preventative measure or treatment for obesity
and diabetes have been investigated using [18F]FDG PET. GLUT1 itself is a potential therapeutic
target for treatment of some diseases, which has also been investigated using [18F]FDG PET.

Keywords: cancer; cardiovascular disease; diabetes; FDG-PET imaging; glucose metabolism;
GLUT1; neurological disorders; positron emission tomography; radiochemistry; transport protein

Contents
1. Introduction
1.1. GLUT facilitative transport proteins
1.2. Glucose transporter GLUT1
1.3. GLUT1 in human health and disease
2. PET imaging using 2-deoxy-2-[18F]fluoro-D-glucose
3. GLUT1 in [18F]FDG PET imaging of cancers
3.1. Introduction
3.2. Lung cancer
3.3. Breast cancer
3.4. Colorectal cancer
3.5. Prostate cancer
3.6. Thyroid cancer
3.7. Esophageal cancer
3.8. Other cancers
3.9. GLUT1 as a therapeutic target in cancer
4. GLUT1 in [18F]FDG PET imaging of neurological disorders
4.1. Introduction
4.2. Alzheimer’s disease
4.3. Parkinson’s disease
4.4. Epileptic disorders
4.5. Schizophrenia
4.6. Multiple sclerosis
4.7. Cerebral ischemia
5. GLUT1 in [18F]FDG PET imaging of cardiovascular diseases
5.1. Introduction
5.2. Heart failure and mycocardial ischemia
5.3. Inflammation
5.4. Cardiac sarcoidosis
5.5. Atherosclerosis
6. Diabetic effects on [18F]FDG PET imaging and roles of GLUT1
6.1. Introduction
6.2. Altered distribution of [18F]FDG in patients with diabetes
6.3. Effects of diabetes on measuring [18F]FDG uptake in the diagnosis of other diseases
6.4. Effects of anti-diabetic drugs
6.5. Brown adipose tissue
6.6. Further roles of GLUT1 in diabetes and therapy
7. Conclusions

http://dx.doi.org/10.17229/jdit.2015-0301-014
ISSN: 2057-3782 (Online)

Page
32
32
32
34
35
39
39
39
41
42
43
43
44
45
46
48
48
48
49
50
51
51
52
53
53
54
54
56
57
59
59
59
61
61
62
64
64

31